SCHEMBL4112941

SCHEMBL4112941

COCc1ccc(NC(=O)Nc2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.60
NPC1 O15118 5/20 0.60
RAB9A P51151 5/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
TAAR1 Q96RJ0 1/20 0.60
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
HTT P42858 1/20 0.58
NLRP1 Q9C000 1/20 0.58
POLB P06746 2/20 0.56
GAA P10253 2/20 0.56
MCL1 Q07820 1/20 0.56
NOX1 Q9Y5S8 1/20 0.56
ALDH1A1 P00352 5/20 0.55
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA9 Q16790 2/20 0.53
TP53 P04637 1/20 0.53
LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117205 0.87 MAPT (0.66) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL4105340 0.87 KMT2A (0.66) MAPTNPC1RAB9ASMN1; SMN2TAAR1
SCHEMBL1104605 0.86 KMT2A (0.61) MAPTRAB9ASMN1; SMN2KMT2AHTT
SCHEMBL4111129 0.83 NPC1 (0.60) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL4112221 0.83 RAB9A (0.63) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3633396 0.82 NPC1 (0.84) MAPTNPC1RAB9ASMN1; SMN2TAAR1
SCHEMBL4105835 0.82 SAE1 (0.76) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL4113109 0.82 ALDH1A1 (0.56) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL13695813 0.82 KMT2A (0.68) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL4107272 0.81 MAPT (0.66) MAPTNPC1RAB9ASMN1; SMN2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885NPC1 927/4885RAB9A 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.